Traditional Chinese Medicine Use in the Treatment of Acute Heart Failure in Western Medicine Hospitals in China: Analysis From the China PEACE Retrospective Heart Failure Study

Yuan Yu, Erica S Spatz, Qi Tan, Shuling Liu, Yuan Lu, Frederick A Masoudi, Wade L Schulz, Harlan M Krumholz, Jing Li, China PEACE Collaborative Group, Yuan Yu, Erica S Spatz, Qi Tan, Shuling Liu, Yuan Lu, Frederick A Masoudi, Wade L Schulz, Harlan M Krumholz, Jing Li, China PEACE Collaborative Group

Abstract

Background Traditional Chinese medicine (TCM) is used in the treatment of many conditions, including heart failure (HF), although it is not well characterized. Methods and Results We conducted a retrospective analysis of TCM use in a random sample of hospitalizations for HF within a random sample of Western medicine hospitals in China in 2015 using data from the China PEACE 5r-HF (China Patient-Centered Evaluative Assessment of Cardiac Events 5 Retrospective Heart Failure Study). We describe the frequency of TCM use and its association with patient characteristics, in-hospital use of evidence-based therapies, and hospital characteristics using hierarchical logistic regression models. Finally, we assessed risk-adjusted in-hospital bleeding and mortality. Among 10 004 patients hospitalized with HF (median age, 73 years; 48.9% women) from 189 hospitals, 74.7% received TCM (83.3% administered intravenously). The most commonly used agent was Salvia miltiorrhiza (51.2%). Patients with coronary artery disease (odds ratio [OR], 1.73; 95% CI, 1.53-1.95) or stroke (OR, 1.32; 95% CI, 1.15-1.51) were more likely to receive TCM; there was no correlation with evidence-based therapy use. Nearly all hospitals (99.4%) used TCM, with substantial variation across hospitals (median OR, 3.29; 95% CI, 2.82-3.76). In-patient bleeding (OR, 1.39; 95% CI, 1.03-1.88) and mortality (OR, 1.36; 95% CI, 1.04-1.79) were higher with Salvia miltiorrhiza, although not with other TCMs. Conclusions In a nationally representative sample of patients hospitalized with acute HF in China, three fourths received TCM. Nearly all hospitals used TCM, although use varied substantially by hospital. Although TCM was not used in lieu of evidence-based therapies for HF, we found a signal for harm with the most commonly used TCM. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT02877914.

Keywords: China; heart failure; hospital variation; traditional Chinese medicine.

Figures

Figure 1
Figure 1
Duration of traditional Chinese medicine (TCM) use during heart failure hospitalization.
Figure 2
Figure 2
Variation of inpatient traditional Chinese medicine (TCM) use among participating hospitals.
Figure 3
Figure 3
Traditional Chinese medicine use by hospital subtype. CABG indicates coronary artery bypass grafting.
Figure 4
Figure 4
Patient‐ and hospital‐level characteristics associated with traditional Chinese medicine (TCM). CABG indicates coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; OR, odds ratio.

References

    1. Lu AP, Ding XR, Chen KJ. Current situation and progress in integrative medicine in China. Chin J Integr Med. 2008;14:234–240.
    1. Spatz ES, Wang Y, Beckman AL, Wu X, Lu Y, Du X, Li J, Xu X, Davidson PM, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. Traditional Chinese medicine for acute myocardial infarction in western medicine hospitals in China. Circ Cardiovasc Qual Outcomes. 2018;11:e004190.
    1. Tsai MY, Hu WL, Lin CC, Lee YC, Chen SY, Hung YC, Chen YH. Prescription pattern of Chinese herbal products for heart failure in Taiwan: a population‐based study. Int J Cardiol. 2017;228:90–96.
    1. Chung V, Wong E, Woo J, Lo SV, Griffiths S. Use of traditional Chinese medicine in the Hong Kong special administrative region of China. J Altern Complement Med. 2007;13:361–367.
    1. Chen X, Li M, Feng F, Chen H, Wu J. Utilization of traditional Chinese medicine for hospitalized heart failure in Fanyu district of Guangzhou. Chin J Inform Tradit Chin Med. 2013;20:97–99.
    1. Hao PP, Jiang F, Chen YG, Yang J, Zhang K, Zhang MX, Zhang C, Zhao YX, Zhang Y. Traditional Chinese medication for cardiovascular disease. Nat Rev Cardiol. 2015;12:115–122.
    1. Wang Y, Wang Q, Li C, Lu L, Zhang Q, Zhu R, Wang W. A review of Chinese herbal medicine for the treatment of chronic heart failure. Curr Pharm Des. 2017;23:5115–5124.
    1. Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol. 2017;69:2952–2966.
    1. Fu S, Zhang J, Gao X, Xia Y, Ferrelli R, Fauci A, Guerra R, Hu L. Clinical practice of traditional Chinese medicines for chronic heart failure. Heart Asia. 2010;2:24–27.
    1. China Society of Cardiology of Chinese Medical Association and Editorial Board of Chinese Journal of Cardiology . Chinese guideline for diagnosis and treatment of heart failure. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42:98–122.
    1. Committee of experts on rational drug use and Chinese pharmacists association . Guideline for rational drug use in heart failure. Chin J Front Med Sci. 2016;8:19–66.
    1. Zhao ZQ, Mao JY, Wang XL, Hou YZ. Application and evaluation of Chinese medicine in treatment of chronic heart failure. Chin J Integr Tradit Western Med. 2013;33:1701–1704.
    1. Xian SX, Yang ZQ, Ren PH, Ye XH, Ye SL, Wang QH, Wang ZH, Shen SJ, Huang XW. Effect of yangxinkang tablets on chronic heart failure: a multi‐center randomized double‐blind placebo‐controlled trial. Chin J Integr Med. 2015;21:733–742.
    1. Xian S, Yang Z, Lee J, Jiang Z, Ye X, Luo L, Jin L, Yang T, Ye S, Lu D. A randomized, double‐blind, multicenter, placebo‐controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. J Ethnopharmacol. 2016;186:136–142.
    1. Wei H, Wu H, Yu W, Yan X, Zhang X. Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure. J Ehnopharmacol. 2015;169:347–355.
    1. Wang C, Zhang Y, Gong LH. Treatment of chronic heart failure by shencao tongmai granule: a multi‐centered, double‐blinded, randomized, parallel controlled trial. Chin J Integr Tradit Western Med. 2012;32:612–615.
    1. Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, Zhang B, Gao R; Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62:1065–1072.
    1. Ma Q, Luo Y, Guo P, Gao G, Yang M, Sablok G, Zhang Y, Zhou F. Clinical effects of Xinmailong therapy in patients with chronic heart failure. Int J Med Sci. 2013;10:624–633.
    1. Yu Y, Zhang H, Li X, Lu Y, Masoudi FA, Krumholz HM, Li J. The China Patient‐centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective heart failure study design. BMJ Open. 2018;8:e020918.
    1. Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe P, Rastam L, Larsen K. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health. 2006;60:290–297.
    1. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010;55:515–525.
    1. Lu S, Chen KJ, Yang QY, Sun HR. Progress in the research of Radix Astragali in treating chronic heart failure: effective ingredients, dose‐effect relationship and adverse reaction. Chin J Integr Med. 2011;17:473–477.
    1. Chen KJ, Lu AP. Situation of integrative medicine in China: results from a national survey in 2004. Chin J Integr Med. 2006;12:161–165.
    1. Tang J‐L, Liu B‐Y, Ma K‐W. Traditional Chinese medicine. Lancet. 2008;372:1938–1940.
    1. Drug List for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance. 2017;2018. Retrieved July 31, 2018. Available at: .
    1. China Statistical Yearbook of Chinese Medicine. 2015;2018. Retrieved June 20, 2018. Available at: .
    1. Wang XL, Liu YM, Zhu GJ. Effects of suxiao jiuxin pill on patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Chin J Integr Tradit Western Med. 2012;32:1483–1487.
    1. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345–1359.
    1. Li H, Liu LT, Zhao WM, Liu JG, Yao MJ, Han YX, Shen YP, Liu XD, Liu L, Wang XM, Cai LL, Guan J. Traditional Chinese versus integrative treatment in elderly patients with isolated systolic hypertension: a multicenter, randomized, double‐blind controlled trial. J Chin Integr Med. 2010;8:410–416.
    1. Kou QA, Yu HP, Zhou GD. Clinical observation on treatment of hypertension (yin‐deficiency with sthenic‐yang syndrome type) with Zhongfu Hypotension Capsule. Chin J Integr Tradit Western Med. 2007;27:745–748.
    1. Venketasubramanian N, Young SH, Tay SS, Umapathi T, Lao AY, Gan HH, Baroque AC II, Navarro JC, Chang HM, Advincula JM, Muengtaweepongsa S, Chan BP, Chua CL, Wijekoon N, de Silva HA, Hiyadan JH, Suwanwela NC, Wong KS, Poungvarin N, Eow GB, Lee CF, Chen CL. CHInese Medicine NeuroAiD Efficacy on Stroke Recovery—Extension Study (CHIMES‐E): a multicenter study of long‐term efficacy. Cerebrovasc Dis. 2015;39:309–318.
    1. He L, Chen X, Zhou M, Zhang D, Yang J, Yang M, Zhou D. Radix/rhizoma notoginseng extract (sanchitongtshu) for ischemic stroke: a randomized controlled study. Phytomedicine. 2011;18:437–442.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner